Sana Biotechnology, Inc. SANA
NASDAQ · United States · Health Technology
$2.87-0.02 (-0.87%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.Sana will present at Citi’s 2026 Biopharma Back-to-School Conf
- Experienced immunology R&D leader Dhavalkumar Patel, M.D., Ph.D., appointed Chair of the company’s Board of Directors - Steven Neier, Ph.D., Senior Director of Venture Investments on the Health team at Leaps by Bayer, will serve as a non-independent director- Appointments come as Paratus advances PS-1001 toward first-in-human studies in 2027 BOSTON and SINGAPORE, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Paratus Sciences (“Paratus”), a global biotechnology company decoding evolution to develop first-i
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet c
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.